Collegium Pharma (COLL) Misses Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Collegium Reports Third Quarter Financial Results
November 8, 2018 4:05 PM ESTNet Product Revenues were $70.2 million for the third quarter of 2018, a 487% increase versus third quarter of 2017Thirteen exclusive ER oxycodone formulary wins announced for Xtampza ER effective January 1, 2019Cash increased by $6.0 million, to $139.8 million as of September 30, 2018; raising year-end cash guidance to $145.0 millionCommercialization Agreement for Nucynta franchise amended to remove guaranteed annual minimum royalty and improves net cash flow for the transaction Conference call scheduled for today at 4:30 p.m. ET
STOUGHTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:... More
